Cargando…

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder

IMPORTANCE: In 2017, the US Food and Drug Administration (FDA) approved a monthly injectable form of buprenorphine, extended-release buprenorphine; published data show that extended-release buprenorphine is effective compared with no treatment, but its current cost is higher and current retention is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flam-Ross, Juliet M., Marsh, Elizabeth, Weitz, Michelle, Savinkina, Alexandra, Schackman, Bruce R., Wang, Jianing, Madushani, R. W. M. A., Morgan, Jake R., Barocas, Joshua A., Walley, Alexander Y., Chrysanthopoulou, Stavroula A., Linas, Benjamin P., Assoumou, Sabrina A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500382/ https://www.ncbi.nlm.nih.gov/pubmed/37703018 http://dx.doi.org/10.1001/jamanetworkopen.2023.29583

Ejemplares similares

Projected Estimates of Opioid Mortality After Community-Level Interventions
por: Linas, Benjamin P., et al.
Publicado: (2021)

Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting
por: Morgan, Jake R., et al.
Publicado: (2020)

Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts
por: Chatterjee, Avik, et al.
Publicado: (2023)

Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study
por: Barocas, Joshua A, et al.
Publicado: (2022)

302. HCV Care in Federally Qualified Health Centers During the Opioid Epidemic: A Retrospective Cohort Study
por: Assoumou, Sabrina A, et al.
Publicado: (2019)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1
por: Linas, Benjamin P., et al.
Publicado: (2016)

Sleep problems in opioid dependent patients maintained on buprenorphine
por: Tripathi, R., et al.
Publicado: (2021)

A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder
por: Kranzler, Henry R, et al.
Publicado: (2020)

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
por: Greenwald, Mark K., et al.
Publicado: (2023)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids
por: Claypool, Anneke L., et al.
Publicado: (2023)

The Hepatitis C Cascade of Care: Identifying Priorities to Improve Clinical Outcomes
por: Linas, Benjamin P., et al.
Publicado: (2014)

HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients
por: Morgan, Jake R., et al.
Publicado: (2021)

Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia
por: Larance, Briony, et al.
Publicado: (2020)

Personalized Care in Opioid Use Disorder maintained on Buprenorphine
por: Elarabi, H., et al.
Publicado: (2022)

Advances in the delivery of buprenorphine for opioid dependence
por: Rosenthal, Richard N, et al.
Publicado: (2017)

Role of Buprenorphine in an Adolescent with Opioid Abuse
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics
por: Jawa, Raagini, et al.
Publicado: (2023)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees
por: Wen, Hefei, et al.
Publicado: (2018)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

A clash of epidemics: Impact of the COVID-19 pandemic response on opioid overdose
por: Linas, Benjamin P., et al.
Publicado: (2021)

Does buprenorphine maintenance improve the quality of life of opioid users?
por: Dhawan, A., et al.
Publicado: (2013)

Extended-release monthly buprenorphine injection
por: Cuperfain, Ari B., et al.
Publicado: (2023)

Treatment of opioid dependence with buprenorphine: current update
por: Soyka, Michael
Publicado: (2017)

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
por: De Aquino, Joao P., et al.
Publicado: (2021)

A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes
por: Lund, Ingunn O., et al.
Publicado: (2013)

Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine
por: Noble, Florence, et al.
Publicado: (2019)

Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome
por: Eudy‐Byrne, Rena, et al.
Publicado: (2021)

Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period
por: Lembke, Anna, et al.
Publicado: (2019)

Evaluating buprenorphine prescribing and opioid-related health outcomes following the expansion the buprenorphine waiver program
por: Rowe, Christopher L., et al.
Publicado: (2022)

Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder
por: Chappuy, Mathieu, et al.
Publicado: (2021)

Injection Site Reaction to Extended-Release Buprenorphine (Sublocade(®)) for Opioid Use Disorder Fourteen Days after Administration
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Buprenorphine for Medication-Assisted Treatment of Opioid Use Disorder in Pregnancy: Relationship to Neonatal Opioid Withdrawal Syndrome
por: Chavan, Niraj R., et al.
Publicado: (2017)

Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals
por: Webster, Lynn R, et al.
Publicado: (2016)

Subcutaneous Extended-Release Buprenorphine Use in Pregnancy
por: Towers, Craig V., et al.
Publicado: (2020)

2570. HCV Screening Practices Among Adolescents and Young Adults in a National Sample of Federally Qualified Health Centers in the United States
por: Epstein, Rachel L, et al.
Publicado: (2018)

Pattern of buprenorphine abuse among opioid abusers in Nepal
por: Aich, Tapas Kumar, et al.
Publicado: (2010)

Comparison of the Efficacy of Buprenorphine and Clonidine in Detoxification of Opioid-Dependents
por: Ziaaddini, Hassan, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_32nonkr3j6ijk0tvb8ros6oabc